188 related articles for article (PubMed ID: 6337292)
1. Immunotherapy of murine leukemia. VIII. Efficacy of passive serum therapy of Friend leukemia virus-induced disease in immunocompromised mice.
Genovesi EV; Livnat D; Collins JJ
J Natl Cancer Inst; 1983 Feb; 70(2):311-22. PubMed ID: 6337292
[TBL] [Abstract][Full Text] [Related]
2. Use of adoptive transfer and Winn assay procedures in the further analysis of antiviral acquired immunity in mice protected against Friend leukemia virus-induced disease by passive serum therapy.
Genovesi EV; Pettey CL; Collins JJ
Cancer Res; 1984 Apr; 44(4):1489-98. PubMed ID: 6608407
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of murine leukemia. V. Protection against Friend leukemia virus-induced immune complex glomerulonephritis by passive serum therapy.
Sanfilippo F; Genovesi EV; Collins JJ
J Natl Cancer Inst; 1981 Sep; 67(3):703-17. PubMed ID: 6456369
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of antiviral resistance by lymphoid cells from mice protected against Friend leukemia virus-induced disease by passive serum therapy.
Collins JJ; Genovesi EV; Livnat D; Sanfilippo F
Cancer Res; 1981 Jun; 41(6):2407-15. PubMed ID: 7016314
[No Abstract] [Full Text] [Related]
5. Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters.
Sanfilippo F; Kao KJ; Pizzo SV; Collins JJ
J Natl Cancer Inst; 1980 Mar; 64(3):547-53. PubMed ID: 6928240
[No Abstract] [Full Text] [Related]
6. Spontaneous regression of Friend murine leukemia virus-induced erythroleukemia. IV. Effects of radiation and athymia on leukemia regression in mice.
Furmanski P; Dietz M; Fouchey S; Hall L; Clymer R; Rich MA
J Natl Cancer Inst; 1979 Aug; 63(2):449-54. PubMed ID: 287833
[TBL] [Abstract][Full Text] [Related]
7. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
Berenson JR; Einstein AB; Fefer A
J Immunol; 1975 Jul; 115(1):234-8. PubMed ID: 1080165
[TBL] [Abstract][Full Text] [Related]
8. Absence of macrophage involvement in the passive serum therapy of Friend leukemia virus-induced disease.
Collins JJ; Snyderman R
Cancer Res; 1980 Mar; 40(3):557-62. PubMed ID: 6258783
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of a murine leukemia virus-infected, chemically induced murine sarcoma with antiviral antibodies.
Ward EC; Iglehart JD; Weinhold KJ; Bolognesi DP
J Natl Cancer Inst; 1982 Aug; 69(2):509-15. PubMed ID: 6955550
[TBL] [Abstract][Full Text] [Related]
10. Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro.
Cheever MA; Kempf RA; Fefer A
J Immunol; 1977 Aug; 119(2):714-8. PubMed ID: 886192
[No Abstract] [Full Text] [Related]
11. Recombinant human interleukin-1 alpha: a potent bio-immunomodifier in vivo in immunosuppressed mice induced by cyclophosphamide, retroviral infection and surgical stress.
Shen RN; Wu B; Lu L; Kaiser HE; Broxmeyer HE
In Vivo; 1994; 8(1):59-63. PubMed ID: 8054512
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of murine leukemia. VII. Prevention of Friend leukemia virus-induced immunosuppression by passive serum therapy.
Genovesi EV; Livnat D; Collins JJ
Int J Cancer; 1982 Nov; 30(5):609-24. PubMed ID: 6984021
[TBL] [Abstract][Full Text] [Related]
13. Suppression of natural killer cell activity by Friend murine leukemia virus.
Moody DJ; Specter S; Bendinelli M; Friedman H
J Natl Cancer Inst; 1984 Jun; 72(6):1349-56. PubMed ID: 6202923
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action.
Sala A; Gresser I; Chassoux D; Maury C; Santodonato L; Eid P; Maunoury MT; Barca S; Cianfriglia M; Belardelli F
Cancer Res; 1992 May; 52(10):2880-9. PubMed ID: 1581903
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of genetic resistance to Friend virus leukemia in mice. V. Relevance of Fv-3 gene in the regulation of in vivo immunosuppression.
Kumar V; Resnick P; Eastcott JW; Bennett M
J Natl Cancer Inst; 1978 Oct; 61(4):1117-23. PubMed ID: 100604
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of murine leukemia. XI. differential susceptibility of spleen cells from serum-protected mice to the in vitro immunosuppressive effects of Friend leukemia virus-infected splenocytes.
Pettey CL; Collins JJ
Int J Cancer; 1984 Aug; 34(2):269-76. PubMed ID: 6540757
[TBL] [Abstract][Full Text] [Related]
17. Natural killer (NK) cells and interferon in Friend-virus-infected susceptible and resistant mice.
Hertenstein B; Kreja L; Seidel HJ
Exp Hematol; 1984 Aug; 12(7):603-9. PubMed ID: 6204881
[TBL] [Abstract][Full Text] [Related]
18. Peptide-induced immune protection of CD8+ T cell-deficient mice against Friend retrovirus-induced disease.
Kawabata H; Niwa A; Tsuji-Kawahara S; Uenishi H; Iwanami N; Matsukuma H; Abe H; Tabata N; Matsumura H; Miyazawa M
Int Immunol; 2006 Jan; 18(1):183-98. PubMed ID: 16352628
[TBL] [Abstract][Full Text] [Related]
19. Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.
Messer RJ; Dittmer U; Peterson KE; Hasenkrug KJ
Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12260-5. PubMed ID: 15297622
[TBL] [Abstract][Full Text] [Related]
20. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
